Phase 1 (or non-severe phase)
In this phase, patient has contracted SARS-CoV-2, the infection starts
and the immune system reacts against the virus. Initial symptoms can be
cough, fatigue, fever, nausea and diarrhea.
The duration of this phase can be three-seven days. During this
non-severe stage, a speciļ¬c adaptive immune response is required to
break down the virus and to avoid the disease progression in the severe
stages. Therefore, strategies to increase the immune responses could be
certainly important. At this stage it can be helpful an antiviral to
inhibit the viral load and avoid complications with the prevention of
virus replication. Probably, an antiviral could be effective to
stimulate the immune system even more at this stage, avoiding the use of
steroid or non-steroid anti-inflammatory drugs, and being able to take
into consideration the administration of immunostimulants or plasma
derived from cured patients.
Currently, there is evidence of efficacy as antivirals for the drugs
remdesivir, lopinavir/ritonavir, chloroquine and hydroxychloroquine.
If the infection is contained in this stage and the virus defeated, this
can be a very good chance of recovery without further complications.